<img src="https://r2cdn.perplexity.ai/pplx-full-logo-primary-dark%402x.png" style="height:64px;margin-right:32px"/>

# Please, I need you to draw up a document for me following the EU's instructions. ([Summaries of Clinical Trial Results for Laypersons](https://health.ec.europa.eu/system/files/2020-02/2017_01_26_summaries_of_ct_results_for_laypersons_0.pdf)- adjunto documento) sobre el estudio de bioequivalencia de Dapagliflozina CInfa (adjunto informe final)

I have created a comprehensive lay summary document of the Dapagliflozin bioequivalence study (CFA-1044-1-24) following the EU's official guidelines for "Summaries of Clinical Trial Results for Laypersons." The document includes all ten mandatory elements per EU Regulation 536/2014 Annex V:

1. **Trial information** - title, protocol number, EU trial number
2. **Sponsor identification** - Laboratorios CINFA
3. **Study contact** - Principal investigator details
4. **Purpose** - Bioequivalence testing between CINFA and Forxiga tablets
5. **Study design** - Two-period crossover in 40 healthy volunteers
6. **Participant information** - Selection criteria, demographics, study locations
7. **Study procedures** - Timeline, fasting conditions, blood sampling protocol
8. **Results (primary outcomes)** - Bioequivalence demonstrated: AUC 101.29% (98.41-104.24), Cmax 98.62% (91.35-106.46)
9. **Safety findings** - 4 mild headaches, 2 dysmenorrhea (unrelated to IMP), no serious adverse events
10. **Conclusions** - Bioequivalence confirmed; both products safe and well-tolerated

The summary adheres to EU health literacy principles: plain language, short sentences, active voice, visual hierarchy, numeracy guidance (presenting absolute numbers and percentages), avoiding jargon, and appropriate for readers aged 12 and above. The document is downloadable in DOCX and PDF formats suitable for regulatory submissions and public disclosure in the EU clinical trial database.
<span style="display:none">[^1][^2][^3]</span>

<div align="center">‚ÅÇ</div>

[^1]: https://health.ec.europa.eu/system/files/2020-02/2017_01_26_summaries_of_ct_results_for_laypersons_0.pdf

[^2]: 2017_01_26_summaries_of_ct_results_for_laypersons_0.pdf

[^3]: CSR-with-appendices.pdf

